


Amendment to the Claims

The claimed invention is:


1. (Currently amended) A compound of formula (A):



or a pharmaceutically acceptable salt, prodrug, tautomer, hydrate or solvate thereof, wherein:

X is O or S;

R¹ is a group of the formula



~~saturated, unsaturated, or aromatic C₃-C₂₀ mono, bi- or polycyclic ring optionally containing at least one heteroatom selected from the group consisting of N, O and S, wherein R¹ can optionally be further independently substituted with at least one moiety independently selected from the group consisting of: carbonyl, halo, halo(C₁-C₆)alkyl, perhalo(C₁-C₆)alkyl, perhalo(C₁-C₆)alkoxy, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, hydroxy, oxo, mercapto, (C₁-C₆)alkylthio, (C₁-C₆)alkoxy, (C₅-C₁₀)aryl or (C₅-C₁₀)heteroaryl, (C₅-C₁₀)aryloxy or (C₅-C₁₀)heteroaryloxy, (C₅-C₁₀)ar(C₁-C₆)alkyl or (C₅-C₁₀)heteroar(C₁-C₆)alkyl,~~

(C₅-C₁₀)ar(C₁-C₆)alkoxy or (C₅-C₁₀)heteroar(C₁-C₆)alkoxy, HO-(C=O)-, ester, amido, ether, amino, amino(C₁-C₆)alkyl, (C₁-C₆)alkylamino(C₁-C₆)alkyl, di(C₁-C₆)alkylamino(C₁-C₆)alkyl, (C₅-C₁₀)heterocyclyl(C₁-C₆)alkyl, (C₁-C₆)alkyl- and di(C₁-C₆)alkylamino, cyano, nitro, carbamoyl, (C₁-C₆)alkylcarbonyl, (C₁-C₆)alkoxycarbonyl, (C₁-C₆)alkylaminocarbonyl, di(C₁-C₆)alkylaminocarbonyl, (C₅-C₁₀)arylcabonyl, (C₅-C₁₀)aryloxycarbonyl, (C₁-C₆)alkylsulfonyl, and (C₅-C₁₀)arylsulfonyl;

each R³ is independently selected from the group consisting of: hydrogen, halo, halo(C₁-C₆)alkyl, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, phenyl, ~~(C₅-C₁₀)heteroaryl~~, ~~(C₅-C₁₀)heterocyclic~~, (C₃-C₁₀)cycloalkyl, hydroxy, (C₁-C₆)alkoxy, perhalo(C₁-C₆)alkoxy, phenoxy, ~~(C₅-C₁₀)heteroaryl-O-~~, ~~(C₅-C₁₀)heterocyclic-O-~~, (C₃-C₁₀)cycloalkyl-O-, (C₁-C₆)alkyl-S-, (C₁-C₆)alkyl-SO₂-, (C₁-C₆)alkyl-NH-SO₂-, O₂N-, NC-, amino, Ph(CH₂)₁₋₆HN-, (C₁-C₆)alkyl HN-, (C₁-C₆)alkylamino, [(C₁-C₆)alkyl]₂-amino, (C₁-C₆)alkyl-SO₂-NH-, amino(C=O)-, aminoO₂S-, (C₁-C₆)alkyl-(C=O)-NH-, (C₁-C₆)alkyl-(C=O)-[((C₁-C₆)alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[(C₁-C₆)alkyl)-N]-, (C₁-C₆)alkyl-(C=O)-, phenyl-(C=O)-, ~~(C₅-C₁₀)heteroaryl-(C=O)-~~, ~~(C₅-C₁₀)heterocyclic-(C=O)-~~, (C₃-C₁₀)cycloalkyl-(C=O)-, HO-(C=O)-, (C₁-C₆)alkyl-O-(C=O)-, H₂N(C=O)-, (C₁-C₆)alkyl-NH-(C=O)-, [(C₁-C₆)alkyl]₂-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[(C₁-C₆)alkyl)-N]-(C=O)-, ~~(C₅-C₁₀)heteroaryl-NH-(C=O)-~~, ~~(C₅-C₁₀)heterocyclic-NH-(C=O)-~~, (C₃-C₁₀)cycloalkyl-NH-(C=O)- and (C₁-C₆)alkyl-(C=O)-O-;

where alkyl, alkenyl, alkynyl, phenyl, ~~heteroaryl~~, ~~heterocyclic~~, cycloalkyl, alkoxy, phenoxy, amino of R³ is optionally substituted by at least one substituent independently selected from (C₁-C₆)alkyl, (C₁-C₆)alkoxy, halo(C₁-C₆)alkyl, halo, H₂N-, Ph(CH₂)₁₋₆HN-, and (C₁-C₆)alkylHN-;

s is an integer from one to five; and

R⁴ is selected from the group consisting of: hydrogen, halo, halo(C₁-C₆)alkyl, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, phenyl, ~~(C₅-C₁₀)heteroaryl~~, ~~(C₅-C₁₀)heterocyclic~~, (C₃-C₁₀)cycloalkyl, hydroxy, (C₁-C₆)alkoxy, perhalo(C₁-C₆)alkoxy, phenoxy,

~~(C₅-C₁₀)heteroaryl-O-~~, ~~(C₅-C₁₀)heterocyclic-O-~~, (C₃-C₁₀)cycloalkyl-O-,
 (C₁-C₆)alkyl-S-, (C₁-C₆)alkyl-SO₂-, (C₁-C₆)alkyl-NH-SO₂-, O₂N-, NC-, amino,
 Ph(CH₂)₁₋₆NH-, alkylNH-, (C₁-C₆)alkylamino, [(C₁-C₆)alkyl]₂-amino,
 (C₁-C₆)alkyl-SO₂-NH-, amino(C=O)-, aminoSO₂-, (C₁-C₆)alkyl-(C=O)-NH-,
 (C₁-C₆)alkyl-(C=O)-((C₁-C₆)alkyl)-N]-, phenyl-(C=O)-NH-,
 phenyl-(C=O)-((C₁-C₆)alkyl)-N]-, (C₁-C₆)alkyl-(C=O)-, phenyl-(C=O)-,
~~(C₅-C₁₀)heteroaryl-(C=O)-~~, ~~(C₅-C₁₀)heterocyclic-(C=O)-~~, cycloalkyl-(C=O)-,
 HO-(C=O)-, (C₁-C₆)alkyl-O-(C=O)-, H₂N(C=O)-, (C₁-C₆)alkyl-NH-(C=O)-,
 ((C₁-C₆)alkyl)₂-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-((C₁-C₆)alkyl)-N]-(C=O)-,
~~(C₅-C₁₀)heteroaryl-NH-(C=O)-~~, ~~(C₅-C₁₀)heterocyclic-NH-(C=O)-~~,
 (C₃-C₁₀)cycloalkyl-NH-(C=O)- and (C₁-C₆)alkyl-(C=O)-O-;

where alkyl, alkenyl, alkynyl, phenyl, ~~heteroaryl~~, ~~heterocyclic~~, cycloalkyl, alkoxy,
 phenoxy, and amino of R⁴ is optionally substituted by at least one substituent independently
 selected from the group consisting of (C₁-C₆)alkyl, (C₁-C₆)alkoxy, halo(C₁-C₆)alkyl, halo,
 H₂N-, Ph(CH₂)₁₋₆-NH-, and (C₁-C₆)alkylNH-.

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Currently Amended) A compound of claim 1, wherein ~~X is O~~; s is one to two; R³ is
 hydrogen or (C₁-C₆)alkyl; and R⁴ is H, (C₁-C₆)alkyl, or (C₃-C₁₀)cycloalkyl.

10. (Cancelled)

11. A pharmaceutical composition comprising a compound of claim 1 and a
 pharmaceutically acceptable carrier.

12. (Cancelled)

13. (Cancelled)

14. (New) A compound 6-[3-(6-Methyl-pyridin-2-yl)-isoxazol-4-yl]-quinoxaline or a pharmaceutically acceptable salt thereof.
15. (New) A pharmaceutical composition comprising 6-[3-(6-Methyl-pyridin-2-yl)-isoxazol-4-yl]-quinoxaline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.